Jacopo Leonardi

Chief Executive Officer at 4D Path

Greater Chicago Area

Overview

Jacopo Leonardi is the Chief Executive Officer of 4D Path Inc., with a notable background in executive leadership roles at companies like Baxalta and Horizon. He holds an MBA from Duke University and specializes in areas such as clinical development, business strategy, and market analysis.

Work Experience

4D Path

Chief Executive Officer
2024 - Current

4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification.

Raised $18,754,108.00.

4dpath.com

Agent Capital

Advisor
2020
Agent Capital, a majority woman-owned international life sciences investment firm, support disruptive healthcare companies focused on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages our industry expertise, and successful track record to source premier deals, accelerate value, and drive successful outcomes.

A biotech venture capital firm.

agentcapital.com

Pheast Therapeutics

Chief Executive Officer
2022 - 2023
Pheast is a preclinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Founded in 2020 as a spinout from Stanford University and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers.

Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.

Raised $76,000,000.00 from Alexandria Venture Investments, Catalio Capital Management, ARCH Venture Partners and Risk & Reward Group.

pheast.com

Horizon

President, Global Commercial Operations
2022 - 2022
Leading US and International Commercial Organizations, Commercial Development, and Global Medical Affairs for Horizon Therapeutics

Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.

Raised $4,458,516,447.00 from Cowen Group, Deerfield, Citigroup Global Markets, Silicon Valley Bank, Oxford Finance LLC and Kreos Capital.

horizontherapeutics.com